Skip to search formSkip to main contentSkip to account menu

PDGFRB NP_002600.1:p.T681I

Known as: Beta Platelet-Derived Growth Factor Receptor Thr681Ile, Platelet-Derived Growth Factor Receptor 1 Thr681Ile, Platelet-Derived Growth Factor Receptor Beta Thr681Ile 
A change in the amino acid residue at position 681 in the platelet-derived growth factor receptor beta protein where threonine has been replaced by… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
PDGRFB mutation‐associated myofibromatosis: Response to targeted therapy with imatinib
Heterozygous activating mutations in platelet‐derived growth factor receptor B (PDGFRB) have been recently identified as a cause… 
2019
2019
Development of mouse models of angiosarcoma driven by p53
ABSTRACT Angiosarcomas are a rare group of tumours which have poor prognosis and limited treatment options. The development of… 
2018
2018
Role of integrin alpha8 in murine model of lung fibrosis
Background Integrin α8 (ITGA8) heterodimerizes with integrin β1 and is highly expressed in stromal cells of the lung. Platelet… 
2017
2017
PDGFRβ-P2A-CreERT2 mice: a genetic tool to target pericytes in angiogenesis
Pericytes are essential mural cells distinguished by their association with small caliber blood vessels and the presence of a… 
2016
2016
Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.
Highly Cited
2013
Highly Cited
2013
Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs
Myofibroblasts are the major source of extracellular matrix components that accumulate during tissue fibrosis, and hepatic… 
2012
2012
Cytogenetic changes in renal cell carcinoma: Basis for sensitivity and resistance to everolimus.
403 Background: The mTOR inhibitors have improved outcomes for pts with metastatic renal cell carcinoma (mRCC) but the duration… 
2012
2012
Preclinical Development Sensitivity ofSelectedHumanTumorModels toPF-04217903 , a Novel Selective c-Met Kinase Inhibitor
The c-Met pathway has been implicated in a variety of human cancers for its critical role in tumor growth, invasion… 
2012
2012
Cytogenetic changes in renal cell carcinoma: Basis for sensitivity and resistance to everolimus.
403 Background: The mTOR inhibitors have improved outcomes for pts with metastatic renal cell carcinoma (mRCC) but the duration… 
2005
2005
The small molecule tyrosine kinase inhibitor AMN 107 inhibits TEL-PDGFR and FIP 1 L 1-PDGFR in vitro and in vivo
AMN107 is a small molecule tyrosine kinase inhibitor developed, in the first instance, as a potent inhibitor of breakpoint… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)